21 October 2022
Near-term gains from outsourcing biopharma R&D activities can be offset by slower innovation in the long run, according to a recent paper.
A study published in Drug Discovery Today found that although outsourcing of biopharma R&D offers productivity benefits, near-term gains can be offset by slower innovation over the long term.
The paper by Billette de Villemeura et al, reviewed the advantages and disadvantages, from the viewpoint of pharmaceutical companies, of sourcing biopharma R&D externally over the use of internal capabilities. It also looked at empirical evidence for the relative efficiency of the two approaches.
Outsourcing was found to offer obvious productivity benefits, including access to new technology, variabilised costs and risk sharing, according to the paper.
However, it suggested that some types of outsourcing promise financial gain for the customers, but risk slower cumulative progress within the innovation ecosystem. “This is because the customers capture so much of the economic value of the outsourced R&D that they undermine the incentives of the suppliers to invest,” the authors said.
In concluding, Billette de Villemeura et al noted:
“We suspect that future analyses of the pros and cons of R&D outsourcing, for both suppliers and customers, would provide clearer answers if they were to make [a] distinction [between the two types of market], rather than treating R&D outsourcing as a single homogenous entity,” the researchers said.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Research calls for greater investment in Alzheimer’s clinical trials
03 May 2024
Stress impact on protein particle formation for monoclonal antibody formulation
03 May 2024
Health Ministry registered Russian drug for ankylosing spondylitis
02 May 2024
Production of finished drugs in Russia grew by 13.8%
02 May 2024